GLP1_NEW
Liraglutide and metformin 1.2 to 1500 mg injection once daily
LIRAMETF_SC_1p2-1500MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.43 (-2.12 to 0.05) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.15 (0.21 to 5.88) | 0.56 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -7.68 (-11.47 to -3.80) | 0.95 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.68 (0.01 to 40.59) | 0.63 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.62 (0.05 to 3.78) | 0.76 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.74 (0.01 to 52.55) | 0.60 |